Thuja Capital Healthcare Seed Fund II | funds

Portfolio Thuja Capital Healthcare Fund II

Company: Atro Medical - Visit website

Fund: Thuja Capital Healthcare Fund II

Year: 2017

Status: Active

Nijmegen based Radboudumc spin-off Atro Medical develops an anatomically shaped polymer based meniscus implant, the Trammpolin, with the aim of restoring the protective function of the meniscus by acting as a joint spacer.

Company: NutriLeads - Visit website

Fund: Thuja Capital Healthcare Fund II

Year: 2015

Status: Active

Wageningen based company active in the field of medical nutrition and functional foods. Currently develops a food ingredient with immune system enhancing properties to help combat infections.

Company: Encare Biotech - Visit website

Fund: Thuja Capital Healthcare Fund II

Year: 2014

Status: Active

Encare Biotech is a spin-off of Utrecht UMC, dedicated to develop antibody therapeutics to prevent chronic heart failure as a consequence of a myocardial infarction.

News
- 17 July 2017, Nijmegen, The Netherlands – Today ATRO Medical announces the successful closure of a Series A financing round. The funding provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund II and includes Brabant Development Agency, DSM Venturing, Cascara Ventures and Radboud university medical center. Read further …
- 7 June 2017, Wageningen, The Netherlands – NUTRILEADS B.V., a Dutch Nutrition & Health startup, together with NIZO food research (consortium leader) and Friesland Campina, has been awarded a €3,7 million EFRO project called CHALLENGE. Read further …
- 23 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the “Offering”) of 6,744,750 American Depositary Shares (“ADSs”), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. Read further …